Organization
Radiation Oncology Department
6 abstracts
Abstract
Survival outcomes associated with first-line PCV or temozolomide in combination with radiotherapy in IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma.Org: Paris Brain Institute (ICM), Service de Neurologie 2 Mazarin, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, AP-HP, Sorbonne Université, Lyon HCL,
Abstract
Ipsilateral recurrence and breast cancer outcomes in carriers of BRCA1/2 pathogenic variants according to locoregional treatments.Org: The Suzanne Levy-Gertner Oncogenetics Unit, Sheba Tel-Hashomer Medical Center, Radiation Oncology Department, The Jusidman Cancer Center, Breast Oncology Institute,
Abstract
Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.Org: Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Universitario Son Espases, Hospital Arnau de Vilanova; GEICAM Spanish Breast Cancer Group,
Abstract
Molecular classification of endometrial carcinoma: Analysis of a multicentre Portuguese cohort.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Portuguese Institute of Oncology - Porto, Radiation Oncology Department, Cancer Biology & Epigenetics Group, Research Center for Health Policy and Economics,
Abstract
Capecitabine-oxaliplatin (CAPOX) prior to chemoradiotherapy (CRT) and surgery in magnetic resonance imaging (MRI)-defined poor-risk rectal carcinoma (PRRC): A single center experience.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Provincial de Castellon, Castellon, Spain, Hospital Provincial de Castellón,
Abstract
Do we need to redefine the Phoenix criteria after the arrival of the new generation imaging techniques?Org: Radiation Oncology Department, Hospital Provincial de Castellón, Consorcio H. Prov. Castellon, Radiotherapy Department, Consorcio hospitalario provincial Castellon,